Global Endogenous Peptide Substances Market Growth (Status and Outlook) 2026-2032
The global Endogenous Peptide Substances market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
LPI (LP Information)' newest research report, the “Endogenous Peptide Substances Industry Forecast” looks at past sales and reviews total world Endogenous Peptide Substances sales in 2025, providing a comprehensive analysis by region and market sector of projected Endogenous Peptide Substances sales for 2026 through 2032. With Endogenous Peptide Substances sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Endogenous Peptide Substances industry.
This Insight Report provides a comprehensive analysis of the global Endogenous Peptide Substances landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Endogenous Peptide Substances portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Endogenous Peptide Substances market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Endogenous Peptide Substances and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Endogenous Peptide Substances.
This report presents a comprehensive overview, market shares, and growth opportunities of Endogenous Peptide Substances market by product type, application, key players and key regions and countries.
Segmentation by Type:
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
LPI (LP Information)' newest research report, the “Endogenous Peptide Substances Industry Forecast” looks at past sales and reviews total world Endogenous Peptide Substances sales in 2025, providing a comprehensive analysis by region and market sector of projected Endogenous Peptide Substances sales for 2026 through 2032. With Endogenous Peptide Substances sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Endogenous Peptide Substances industry.
This Insight Report provides a comprehensive analysis of the global Endogenous Peptide Substances landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Endogenous Peptide Substances portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Endogenous Peptide Substances market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Endogenous Peptide Substances and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Endogenous Peptide Substances.
This report presents a comprehensive overview, market shares, and growth opportunities of Endogenous Peptide Substances market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Neuropeptides
- Hormones
- Cytokines
- Peptide Hormones
- Bioactive Peptides
- Research
- Medicine
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Assertio Therapeutics Inc.
- Cipher Pharmaceuticals Inc.
- Endo International Plc
- Biosynth Carbosynth
- Lannett Co. Inc.
- Pfizer
- Johnson & Johnson
- Peptide Institute
- Abbexa
- Phoenix Pharmaceuticals
- Creative Peptides
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Endogenous Peptide Substances Market Size (2021-2032)
2.1.2 Endogenous Peptide Substances Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Endogenous Peptide Substances by Country/Region (2021, 2025 & 2032)
2.2 Endogenous Peptide Substances Segment by Type
2.2.1 Neuropeptides
2.2.2 Hormones
2.2.3 Cytokines
2.2.4 Peptide Hormones
2.2.5 Bioactive Peptides
2.2.6 Endogenous Peptide Substances Market Size by Type
2.2.6.1 Endogenous Peptide Substances Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
2.3 Endogenous Peptide Substances Segment by Application
2.3.1 Research
2.3.2 Medicine
2.3.3 Others
2.3.4 Endogenous Peptide Substances Market Size by Application
2.3.4.1 Endogenous Peptide Substances Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
3 ENDOGENOUS PEPTIDE SUBSTANCES MARKET SIZE BY PLAYER
3.1 Endogenous Peptide Substances Market Size Market Share by Player
3.1.1 Global Endogenous Peptide Substances Revenue by Player (2021-2026)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Player (2021-2026)
3.2 Global Endogenous Peptide Substances Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ENDOGENOUS PEPTIDE SUBSTANCES BY REGION
4.1 Endogenous Peptide Substances Market Size by Region (2021-2026)
4.2 Global Endogenous Peptide Substances Annual Revenue by Country/Region (2021-2026)
4.3 Americas Endogenous Peptide Substances Market Size Growth (2021-2026)
4.4 APAC Endogenous Peptide Substances Market Size Growth (2021-2026)
4.5 Europe Endogenous Peptide Substances Market Size Growth (2021-2026)
4.6 Middle East & Africa Endogenous Peptide Substances Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Endogenous Peptide Substances Market Size by Country (2021-2026)
5.2 Americas Endogenous Peptide Substances Market Size by Type (2021-2026)
5.3 Americas Endogenous Peptide Substances Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endogenous Peptide Substances Market Size by Region (2021-2026)
6.2 APAC Endogenous Peptide Substances Market Size by Type (2021-2026)
6.3 APAC Endogenous Peptide Substances Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Endogenous Peptide Substances Market Size by Country (2021-2026)
7.2 Europe Endogenous Peptide Substances Market Size by Type (2021-2026)
7.3 Europe Endogenous Peptide Substances Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Endogenous Peptide Substances by Region (2021-2026)
8.2 Middle East & Africa Endogenous Peptide Substances Market Size by Type (2021-2026)
8.3 Middle East & Africa Endogenous Peptide Substances Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ENDOGENOUS PEPTIDE SUBSTANCES MARKET FORECAST
10.1 Global Endogenous Peptide Substances Forecast by Region (2027-2032)
10.1.1 Global Endogenous Peptide Substances Forecast by Region (2027-2032)
10.1.2 Americas Endogenous Peptide Substances Forecast
10.1.3 APAC Endogenous Peptide Substances Forecast
10.1.4 Europe Endogenous Peptide Substances Forecast
10.1.5 Middle East & Africa Endogenous Peptide Substances Forecast
10.2 Americas Endogenous Peptide Substances Forecast by Country (2027-2032)
10.2.1 United States Market Endogenous Peptide Substances Forecast
10.2.2 Canada Market Endogenous Peptide Substances Forecast
10.2.3 Mexico Market Endogenous Peptide Substances Forecast
10.2.4 Brazil Market Endogenous Peptide Substances Forecast
10.3 APAC Endogenous Peptide Substances Forecast by Region (2027-2032)
10.3.1 China Endogenous Peptide Substances Market Forecast
10.3.2 Japan Market Endogenous Peptide Substances Forecast
10.3.3 Korea Market Endogenous Peptide Substances Forecast
10.3.4 Southeast Asia Market Endogenous Peptide Substances Forecast
10.3.5 India Market Endogenous Peptide Substances Forecast
10.3.6 Australia Market Endogenous Peptide Substances Forecast
10.4 Europe Endogenous Peptide Substances Forecast by Country (2027-2032)
10.4.1 Germany Market Endogenous Peptide Substances Forecast
10.4.2 France Market Endogenous Peptide Substances Forecast
10.4.3 UK Market Endogenous Peptide Substances Forecast
10.4.4 Italy Market Endogenous Peptide Substances Forecast
10.4.5 Russia Market Endogenous Peptide Substances Forecast
10.5 Middle East & Africa Endogenous Peptide Substances Forecast by Region (2027-2032)
10.5.1 Egypt Market Endogenous Peptide Substances Forecast
10.5.2 South Africa Market Endogenous Peptide Substances Forecast
10.5.3 Israel Market Endogenous Peptide Substances Forecast
10.5.4 Turkey Market Endogenous Peptide Substances Forecast
10.6 Global Endogenous Peptide Substances Forecast by Type (2027-2032)
10.7 Global Endogenous Peptide Substances Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Endogenous Peptide Substances Forecast
11 KEY PLAYERS ANALYSIS
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Information
11.1.2 Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Assertio Therapeutics Inc. Main Business Overview
11.1.5 Assertio Therapeutics Inc. Latest Developments
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Information
11.2.2 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Cipher Pharmaceuticals Inc. Main Business Overview
11.2.5 Cipher Pharmaceuticals Inc. Latest Developments
11.3 Endo International Plc
11.3.1 Endo International Plc Company Information
11.3.2 Endo International Plc Endogenous Peptide Substances Product Offered
11.3.3 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Endo International Plc Main Business Overview
11.3.5 Endo International Plc Latest Developments
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Information
11.4.2 Biosynth Carbosynth Endogenous Peptide Substances Product Offered
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biosynth Carbosynth Main Business Overview
11.4.5 Biosynth Carbosynth Latest Developments
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Information
11.5.2 Lannett Co. Inc. Endogenous Peptide Substances Product Offered
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Lannett Co. Inc. Main Business Overview
11.5.5 Lannett Co. Inc. Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Endogenous Peptide Substances Product Offered
11.6.3 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Endogenous Peptide Substances Product Offered
11.7.3 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Johnson & Johnson Main Business Overview
11.7.5 Johnson & Johnson Latest Developments
11.8 Peptide Institute
11.8.1 Peptide Institute Company Information
11.8.2 Peptide Institute Endogenous Peptide Substances Product Offered
11.8.3 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Peptide Institute Main Business Overview
11.8.5 Peptide Institute Latest Developments
11.9 Abbexa
11.9.1 Abbexa Company Information
11.9.2 Abbexa Endogenous Peptide Substances Product Offered
11.9.3 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Abbexa Main Business Overview
11.9.5 Abbexa Latest Developments
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Information
11.10.2 Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Phoenix Pharmaceuticals Main Business Overview
11.10.5 Phoenix Pharmaceuticals Latest Developments
11.11 Creative Peptides
11.11.1 Creative Peptides Company Information
11.11.2 Creative Peptides Endogenous Peptide Substances Product Offered
11.11.3 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Creative Peptides Main Business Overview
11.11.5 Creative Peptides Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Endogenous Peptide Substances Market Size (2021-2032)
2.1.2 Endogenous Peptide Substances Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Endogenous Peptide Substances by Country/Region (2021, 2025 & 2032)
2.2 Endogenous Peptide Substances Segment by Type
2.2.1 Neuropeptides
2.2.2 Hormones
2.2.3 Cytokines
2.2.4 Peptide Hormones
2.2.5 Bioactive Peptides
2.2.6 Endogenous Peptide Substances Market Size by Type
2.2.6.1 Endogenous Peptide Substances Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
2.3 Endogenous Peptide Substances Segment by Application
2.3.1 Research
2.3.2 Medicine
2.3.3 Others
2.3.4 Endogenous Peptide Substances Market Size by Application
2.3.4.1 Endogenous Peptide Substances Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
3 ENDOGENOUS PEPTIDE SUBSTANCES MARKET SIZE BY PLAYER
3.1 Endogenous Peptide Substances Market Size Market Share by Player
3.1.1 Global Endogenous Peptide Substances Revenue by Player (2021-2026)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Player (2021-2026)
3.2 Global Endogenous Peptide Substances Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ENDOGENOUS PEPTIDE SUBSTANCES BY REGION
4.1 Endogenous Peptide Substances Market Size by Region (2021-2026)
4.2 Global Endogenous Peptide Substances Annual Revenue by Country/Region (2021-2026)
4.3 Americas Endogenous Peptide Substances Market Size Growth (2021-2026)
4.4 APAC Endogenous Peptide Substances Market Size Growth (2021-2026)
4.5 Europe Endogenous Peptide Substances Market Size Growth (2021-2026)
4.6 Middle East & Africa Endogenous Peptide Substances Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Endogenous Peptide Substances Market Size by Country (2021-2026)
5.2 Americas Endogenous Peptide Substances Market Size by Type (2021-2026)
5.3 Americas Endogenous Peptide Substances Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endogenous Peptide Substances Market Size by Region (2021-2026)
6.2 APAC Endogenous Peptide Substances Market Size by Type (2021-2026)
6.3 APAC Endogenous Peptide Substances Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Endogenous Peptide Substances Market Size by Country (2021-2026)
7.2 Europe Endogenous Peptide Substances Market Size by Type (2021-2026)
7.3 Europe Endogenous Peptide Substances Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Endogenous Peptide Substances by Region (2021-2026)
8.2 Middle East & Africa Endogenous Peptide Substances Market Size by Type (2021-2026)
8.3 Middle East & Africa Endogenous Peptide Substances Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ENDOGENOUS PEPTIDE SUBSTANCES MARKET FORECAST
10.1 Global Endogenous Peptide Substances Forecast by Region (2027-2032)
10.1.1 Global Endogenous Peptide Substances Forecast by Region (2027-2032)
10.1.2 Americas Endogenous Peptide Substances Forecast
10.1.3 APAC Endogenous Peptide Substances Forecast
10.1.4 Europe Endogenous Peptide Substances Forecast
10.1.5 Middle East & Africa Endogenous Peptide Substances Forecast
10.2 Americas Endogenous Peptide Substances Forecast by Country (2027-2032)
10.2.1 United States Market Endogenous Peptide Substances Forecast
10.2.2 Canada Market Endogenous Peptide Substances Forecast
10.2.3 Mexico Market Endogenous Peptide Substances Forecast
10.2.4 Brazil Market Endogenous Peptide Substances Forecast
10.3 APAC Endogenous Peptide Substances Forecast by Region (2027-2032)
10.3.1 China Endogenous Peptide Substances Market Forecast
10.3.2 Japan Market Endogenous Peptide Substances Forecast
10.3.3 Korea Market Endogenous Peptide Substances Forecast
10.3.4 Southeast Asia Market Endogenous Peptide Substances Forecast
10.3.5 India Market Endogenous Peptide Substances Forecast
10.3.6 Australia Market Endogenous Peptide Substances Forecast
10.4 Europe Endogenous Peptide Substances Forecast by Country (2027-2032)
10.4.1 Germany Market Endogenous Peptide Substances Forecast
10.4.2 France Market Endogenous Peptide Substances Forecast
10.4.3 UK Market Endogenous Peptide Substances Forecast
10.4.4 Italy Market Endogenous Peptide Substances Forecast
10.4.5 Russia Market Endogenous Peptide Substances Forecast
10.5 Middle East & Africa Endogenous Peptide Substances Forecast by Region (2027-2032)
10.5.1 Egypt Market Endogenous Peptide Substances Forecast
10.5.2 South Africa Market Endogenous Peptide Substances Forecast
10.5.3 Israel Market Endogenous Peptide Substances Forecast
10.5.4 Turkey Market Endogenous Peptide Substances Forecast
10.6 Global Endogenous Peptide Substances Forecast by Type (2027-2032)
10.7 Global Endogenous Peptide Substances Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Endogenous Peptide Substances Forecast
11 KEY PLAYERS ANALYSIS
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Information
11.1.2 Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Assertio Therapeutics Inc. Main Business Overview
11.1.5 Assertio Therapeutics Inc. Latest Developments
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Information
11.2.2 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Cipher Pharmaceuticals Inc. Main Business Overview
11.2.5 Cipher Pharmaceuticals Inc. Latest Developments
11.3 Endo International Plc
11.3.1 Endo International Plc Company Information
11.3.2 Endo International Plc Endogenous Peptide Substances Product Offered
11.3.3 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Endo International Plc Main Business Overview
11.3.5 Endo International Plc Latest Developments
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Information
11.4.2 Biosynth Carbosynth Endogenous Peptide Substances Product Offered
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biosynth Carbosynth Main Business Overview
11.4.5 Biosynth Carbosynth Latest Developments
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Information
11.5.2 Lannett Co. Inc. Endogenous Peptide Substances Product Offered
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Lannett Co. Inc. Main Business Overview
11.5.5 Lannett Co. Inc. Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Endogenous Peptide Substances Product Offered
11.6.3 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Endogenous Peptide Substances Product Offered
11.7.3 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Johnson & Johnson Main Business Overview
11.7.5 Johnson & Johnson Latest Developments
11.8 Peptide Institute
11.8.1 Peptide Institute Company Information
11.8.2 Peptide Institute Endogenous Peptide Substances Product Offered
11.8.3 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Peptide Institute Main Business Overview
11.8.5 Peptide Institute Latest Developments
11.9 Abbexa
11.9.1 Abbexa Company Information
11.9.2 Abbexa Endogenous Peptide Substances Product Offered
11.9.3 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Abbexa Main Business Overview
11.9.5 Abbexa Latest Developments
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Information
11.10.2 Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Phoenix Pharmaceuticals Main Business Overview
11.10.5 Phoenix Pharmaceuticals Latest Developments
11.11 Creative Peptides
11.11.1 Creative Peptides Company Information
11.11.2 Creative Peptides Endogenous Peptide Substances Product Offered
11.11.3 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Creative Peptides Main Business Overview
11.11.5 Creative Peptides Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Endogenous Peptide Substances Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Endogenous Peptide Substances Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Neuropeptides
Table 4. Major Players of Hormones
Table 5. Major Players of Cytokines
Table 6. Major Players of Peptide Hormones
Table 7. Major Players of Bioactive Peptides
Table 8. Endogenous Peptide Substances Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Table 11. Endogenous Peptide Substances Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 13. Global Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Table 14. Global Endogenous Peptide Substances Revenue by Player (2021-2026) & ($ millions)
Table 15. Global Endogenous Peptide Substances Revenue Market Share by Player (2021-2026)
Table 16. Endogenous Peptide Substances Key Players Head office and Products Offered
Table 17. Endogenous Peptide Substances Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Endogenous Peptide Substances Market Size by Region (2021-2026) & ($ millions)
Table 21. Global Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Table 22. Global Endogenous Peptide Substances Revenue by Country/Region (2021-2026) & ($ millions)
Table 23. Global Endogenous Peptide Substances Revenue Market Share by Country/Region (2021-2026)
Table 24. Americas Endogenous Peptide Substances Market Size by Country (2021-2026) & ($ millions)
Table 25. Americas Endogenous Peptide Substances Market Size Market Share by Country (2021-2026)
Table 26. Americas Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 27. Americas Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Table 28. Americas Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 29. Americas Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Table 30. APAC Endogenous Peptide Substances Market Size by Region (2021-2026) & ($ millions)
Table 31. APAC Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Table 32. APAC Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 33. APAC Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 34. Europe Endogenous Peptide Substances Market Size by Country (2021-2026) & ($ millions)
Table 35. Europe Endogenous Peptide Substances Market Size Market Share by Country (2021-2026)
Table 36. Europe Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 37. Europe Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 38. Middle East & Africa Endogenous Peptide Substances Market Size by Region (2021-2026) & ($ millions)
Table 39. Middle East & Africa Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 40. Middle East & Africa Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Endogenous Peptide Substances
Table 42. Key Market Challenges & Risks of Endogenous Peptide Substances
Table 43. Key Industry Trends of Endogenous Peptide Substances
Table 44. Global Endogenous Peptide Substances Market Size Forecast by Region (2027-2032) & ($ millions)
Table 45. Global Endogenous Peptide Substances Market Size Market Share Forecast by Region (2027-2032)
Table 46. Global Endogenous Peptide Substances Market Size Forecast by Type (2027-2032) & ($ millions)
Table 47. Global Endogenous Peptide Substances Market Size Forecast by Application (2027-2032) & ($ millions)
Table 48. Assertio Therapeutics Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 49. Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
Table 50. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 51. Assertio Therapeutics Inc. Main Business
Table 52. Assertio Therapeutics Inc. Latest Developments
Table 53. Cipher Pharmaceuticals Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 54. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
Table 55. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 56. Cipher Pharmaceuticals Inc. Main Business
Table 57. Cipher Pharmaceuticals Inc. Latest Developments
Table 58. Endo International Plc Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 59. Endo International Plc Endogenous Peptide Substances Product Offered
Table 60. Endo International Plc Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Endo International Plc Main Business
Table 62. Endo International Plc Latest Developments
Table 63. Biosynth Carbosynth Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 64. Biosynth Carbosynth Endogenous Peptide Substances Product Offered
Table 65. Biosynth Carbosynth Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. Biosynth Carbosynth Main Business
Table 67. Biosynth Carbosynth Latest Developments
Table 68. Lannett Co. Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 69. Lannett Co. Inc. Endogenous Peptide Substances Product Offered
Table 70. Lannett Co. Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Lannett Co. Inc. Main Business
Table 72. Lannett Co. Inc. Latest Developments
Table 73. Pfizer Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 74. Pfizer Endogenous Peptide Substances Product Offered
Table 75. Pfizer Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Johnson & Johnson Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 79. Johnson & Johnson Endogenous Peptide Substances Product Offered
Table 80. Johnson & Johnson Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Johnson & Johnson Main Business
Table 82. Johnson & Johnson Latest Developments
Table 83. Peptide Institute Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 84. Peptide Institute Endogenous Peptide Substances Product Offered
Table 85. Peptide Institute Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Peptide Institute Main Business
Table 87. Peptide Institute Latest Developments
Table 88. Abbexa Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 89. Abbexa Endogenous Peptide Substances Product Offered
Table 90. Abbexa Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Abbexa Main Business
Table 92. Abbexa Latest Developments
Table 93. Phoenix Pharmaceuticals Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 94. Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
Table 95. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Phoenix Pharmaceuticals Main Business
Table 97. Phoenix Pharmaceuticals Latest Developments
Table 98. Creative Peptides Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 99. Creative Peptides Endogenous Peptide Substances Product Offered
Table 100. Creative Peptides Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Creative Peptides Main Business
Table 102. Creative Peptides Latest Developments
Table 1. Endogenous Peptide Substances Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Endogenous Peptide Substances Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Neuropeptides
Table 4. Major Players of Hormones
Table 5. Major Players of Cytokines
Table 6. Major Players of Peptide Hormones
Table 7. Major Players of Bioactive Peptides
Table 8. Endogenous Peptide Substances Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Table 11. Endogenous Peptide Substances Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 12. Global Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 13. Global Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Table 14. Global Endogenous Peptide Substances Revenue by Player (2021-2026) & ($ millions)
Table 15. Global Endogenous Peptide Substances Revenue Market Share by Player (2021-2026)
Table 16. Endogenous Peptide Substances Key Players Head office and Products Offered
Table 17. Endogenous Peptide Substances Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Endogenous Peptide Substances Market Size by Region (2021-2026) & ($ millions)
Table 21. Global Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Table 22. Global Endogenous Peptide Substances Revenue by Country/Region (2021-2026) & ($ millions)
Table 23. Global Endogenous Peptide Substances Revenue Market Share by Country/Region (2021-2026)
Table 24. Americas Endogenous Peptide Substances Market Size by Country (2021-2026) & ($ millions)
Table 25. Americas Endogenous Peptide Substances Market Size Market Share by Country (2021-2026)
Table 26. Americas Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 27. Americas Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Table 28. Americas Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 29. Americas Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Table 30. APAC Endogenous Peptide Substances Market Size by Region (2021-2026) & ($ millions)
Table 31. APAC Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Table 32. APAC Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 33. APAC Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 34. Europe Endogenous Peptide Substances Market Size by Country (2021-2026) & ($ millions)
Table 35. Europe Endogenous Peptide Substances Market Size Market Share by Country (2021-2026)
Table 36. Europe Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 37. Europe Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 38. Middle East & Africa Endogenous Peptide Substances Market Size by Region (2021-2026) & ($ millions)
Table 39. Middle East & Africa Endogenous Peptide Substances Market Size by Type (2021-2026) & ($ millions)
Table 40. Middle East & Africa Endogenous Peptide Substances Market Size by Application (2021-2026) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Endogenous Peptide Substances
Table 42. Key Market Challenges & Risks of Endogenous Peptide Substances
Table 43. Key Industry Trends of Endogenous Peptide Substances
Table 44. Global Endogenous Peptide Substances Market Size Forecast by Region (2027-2032) & ($ millions)
Table 45. Global Endogenous Peptide Substances Market Size Market Share Forecast by Region (2027-2032)
Table 46. Global Endogenous Peptide Substances Market Size Forecast by Type (2027-2032) & ($ millions)
Table 47. Global Endogenous Peptide Substances Market Size Forecast by Application (2027-2032) & ($ millions)
Table 48. Assertio Therapeutics Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 49. Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
Table 50. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 51. Assertio Therapeutics Inc. Main Business
Table 52. Assertio Therapeutics Inc. Latest Developments
Table 53. Cipher Pharmaceuticals Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 54. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
Table 55. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 56. Cipher Pharmaceuticals Inc. Main Business
Table 57. Cipher Pharmaceuticals Inc. Latest Developments
Table 58. Endo International Plc Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 59. Endo International Plc Endogenous Peptide Substances Product Offered
Table 60. Endo International Plc Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Endo International Plc Main Business
Table 62. Endo International Plc Latest Developments
Table 63. Biosynth Carbosynth Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 64. Biosynth Carbosynth Endogenous Peptide Substances Product Offered
Table 65. Biosynth Carbosynth Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. Biosynth Carbosynth Main Business
Table 67. Biosynth Carbosynth Latest Developments
Table 68. Lannett Co. Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 69. Lannett Co. Inc. Endogenous Peptide Substances Product Offered
Table 70. Lannett Co. Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Lannett Co. Inc. Main Business
Table 72. Lannett Co. Inc. Latest Developments
Table 73. Pfizer Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 74. Pfizer Endogenous Peptide Substances Product Offered
Table 75. Pfizer Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Johnson & Johnson Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 79. Johnson & Johnson Endogenous Peptide Substances Product Offered
Table 80. Johnson & Johnson Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. Johnson & Johnson Main Business
Table 82. Johnson & Johnson Latest Developments
Table 83. Peptide Institute Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 84. Peptide Institute Endogenous Peptide Substances Product Offered
Table 85. Peptide Institute Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Peptide Institute Main Business
Table 87. Peptide Institute Latest Developments
Table 88. Abbexa Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 89. Abbexa Endogenous Peptide Substances Product Offered
Table 90. Abbexa Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. Abbexa Main Business
Table 92. Abbexa Latest Developments
Table 93. Phoenix Pharmaceuticals Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 94. Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
Table 95. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Phoenix Pharmaceuticals Main Business
Table 97. Phoenix Pharmaceuticals Latest Developments
Table 98. Creative Peptides Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 99. Creative Peptides Endogenous Peptide Substances Product Offered
Table 100. Creative Peptides Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Creative Peptides Main Business
Table 102. Creative Peptides Latest Developments
LIST OF FIGURES
Figure 1. Endogenous Peptide Substances Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Endogenous Peptide Substances Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Endogenous Peptide Substances Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Endogenous Peptide Substances Sales Market Share by Country/Region (2025)
Figure 8. Endogenous Peptide Substances Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Endogenous Peptide Substances Market Size Market Share by Type in 2025
Figure 10. Endogenous Peptide Substances in Research
Figure 11. Global Endogenous Peptide Substances Market: Research (2021-2026) & ($ millions)
Figure 12. Endogenous Peptide Substances in Medicine
Figure 13. Global Endogenous Peptide Substances Market: Medicine (2021-2026) & ($ millions)
Figure 14. Endogenous Peptide Substances in Others
Figure 15. Global Endogenous Peptide Substances Market: Others (2021-2026) & ($ millions)
Figure 16. Global Endogenous Peptide Substances Market Size Market Share by Application in 2025
Figure 17. Global Endogenous Peptide Substances Revenue Market Share by Player in 2025
Figure 18. Global Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Figure 19. Americas Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 20. APAC Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 21. Europe Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 23. Americas Endogenous Peptide Substances Value Market Share by Country in 2025
Figure 24. United States Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Endogenous Peptide Substances Market Size Market Share by Region in 2025
Figure 29. APAC Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Figure 30. APAC Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Figure 31. China Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 35. India Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Endogenous Peptide Substances Market Size Market Share by Country in 2025
Figure 38. Europe Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Figure 39. Europe Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Figure 40. Germany Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 41. France Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 54. APAC Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 55. Europe Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 57. United States Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 58. Canada Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 59. Mexico Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 60. Brazil Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 61. China Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 62. Japan Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 63. Korea Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 65. India Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 66. Australia Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 67. Germany Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 68. France Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 69. UK Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 70. Italy Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 71. Russia Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 72. Egypt Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 73. South Africa Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 74. Israel Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 75. Turkey Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 76. Global Endogenous Peptide Substances Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Endogenous Peptide Substances Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 1. Endogenous Peptide Substances Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Endogenous Peptide Substances Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Endogenous Peptide Substances Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Endogenous Peptide Substances Sales Market Share by Country/Region (2025)
Figure 8. Endogenous Peptide Substances Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Endogenous Peptide Substances Market Size Market Share by Type in 2025
Figure 10. Endogenous Peptide Substances in Research
Figure 11. Global Endogenous Peptide Substances Market: Research (2021-2026) & ($ millions)
Figure 12. Endogenous Peptide Substances in Medicine
Figure 13. Global Endogenous Peptide Substances Market: Medicine (2021-2026) & ($ millions)
Figure 14. Endogenous Peptide Substances in Others
Figure 15. Global Endogenous Peptide Substances Market: Others (2021-2026) & ($ millions)
Figure 16. Global Endogenous Peptide Substances Market Size Market Share by Application in 2025
Figure 17. Global Endogenous Peptide Substances Revenue Market Share by Player in 2025
Figure 18. Global Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Figure 19. Americas Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 20. APAC Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 21. Europe Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Endogenous Peptide Substances Market Size 2021-2026 ($ millions)
Figure 23. Americas Endogenous Peptide Substances Value Market Share by Country in 2025
Figure 24. United States Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Endogenous Peptide Substances Market Size Market Share by Region in 2025
Figure 29. APAC Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Figure 30. APAC Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Figure 31. China Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 35. India Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Endogenous Peptide Substances Market Size Market Share by Country in 2025
Figure 38. Europe Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Figure 39. Europe Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Figure 40. Germany Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 41. France Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Endogenous Peptide Substances Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 54. APAC Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 55. Europe Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 57. United States Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 58. Canada Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 59. Mexico Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 60. Brazil Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 61. China Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 62. Japan Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 63. Korea Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 65. India Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 66. Australia Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 67. Germany Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 68. France Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 69. UK Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 70. Italy Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 71. Russia Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 72. Egypt Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 73. South Africa Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 74. Israel Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 75. Turkey Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
Figure 76. Global Endogenous Peptide Substances Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Endogenous Peptide Substances Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Endogenous Peptide Substances Market Size 2027-2032 ($ millions)
